Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis

Equine Vet J. 2017 May;49(3):345-351. doi: 10.1111/evj.12603. Epub 2016 Aug 16.

Abstract

Background: The roles of soluble epoxide hydrolase and lipid mediators in inflammatory and neuropathic pain could be relevant in laminitis pain management.

Objectives: To determine soluble epoxide hydrolase (sEH) activity in the digital laminae, sEH inhibitor potency in vitro, and efficacy of a sEH inhibitor as an adjunct analgesic therapy in chronic laminitic horses.

Study design: In vitro experiments and clinical case series.

Methods: sEH activity was measured in digital laminae from euthanised healthy and laminitic horses (n = 5-6/group). Potency of 7 synthetic sEH inhibitors was determined in vitro using equine liver cytosol. One of them (t-TUCB; 0.1 mg/kg bwt i.v. every 24 h) was selected based on potency and stability, and used as adjunct therapy in 10 horses with severe chronic laminitis (Obel grades 2, one horse; 3-4, nine horses). Daily assessments of forelimb lifts, pain scores, physiologic and laboratory examinations were performed before (baseline) and during t-TUCB treatment. Data are presented as mean ± s.d. and 95% confidence intervals (CI).

Results: sEH activity in the digital laminae from laminitic horses (0.9±0.6 nmol/min/mg; 95% CI 0.16-1.55 nmol/min/mg) was significantly greater (P = 0.01) than in healthy horses (0.17±0.09 nmol/min/mg; CI 0.07-0.26 nmol/min/mg). t-TUCB as an adjunct analgesic up to 10 days (4.3±3 days) in laminitic horses was associated with significant reduction in forelimb lifts (36±22%; 95% CI 9-64%) and in pain scores (18±23%; 95% CI 2-35%) compared with baseline (P = 0.04). One horse developed gas colic and another corneal vascularisation in a blind eye during treatment. No other significant changes were observed.

Main limitations: Absence of control group and evaluator blinding in case series.

Conclusions: sEH activity is significantly higher in the digital laminae of actively laminitic compared with healthy horses, and use of a potent inhibitor of equine sEH as adjunct analgesic therapy appears to decrease signs of pathologic pain in laminitic horses.

Keywords: fatty acid; hoof; horse; hyperalgesia; lameness; neuropathic pain.

Publication types

  • Clinical Trial

MeSH terms

  • Animals
  • Benzoates / chemistry
  • Benzoates / pharmacology
  • Benzoates / therapeutic use*
  • Chronic Disease
  • Epoxide Hydrolases / antagonists & inhibitors
  • Epoxide Hydrolases / genetics
  • Epoxide Hydrolases / metabolism*
  • Female
  • Foot Diseases / drug therapy
  • Foot Diseases / enzymology
  • Foot Diseases / veterinary*
  • Hoof and Claw / pathology*
  • Horse Diseases / enzymology*
  • Horse Diseases / metabolism
  • Horse Diseases / pathology
  • Horses
  • Inflammation / drug therapy
  • Inflammation / enzymology
  • Inflammation / veterinary*
  • Liver / enzymology
  • Male
  • Molecular Structure
  • Phenylurea Compounds / chemistry
  • Phenylurea Compounds / pharmacology
  • Phenylurea Compounds / therapeutic use*

Substances

  • 4-(4-(3-(4-trifluoromethoxy-phenyl)ureido)cyclohexyloxy)benzoic acid
  • Benzoates
  • Phenylurea Compounds
  • Epoxide Hydrolases